[Maiway Bio: 9MW2821 clinical data will be presented in an oral report at the 2026 ESMO Conference] On October 18, Maiwei Bio (688062.SH) announced that the company will announce the phase II clinical data of the innovative drug 9MW2821 targeting nectin-4 ADC for patients with triple-negative breast cancer (TNBC) in the form of an oral report at the 2026 European Society for Medical Oncology (ESMO) Congress. As of April 10, 2026, among 60 patients with evaluable efficacy, the objective response rate (ORR) was 30.0%, the disease control rate (DCR) was 80.0%, the median progression-free survival (mPFS) was 3.7 months, the median duration of response (mDOR) was 8.7 months, the median overall survival (mOS) has not yet matured, and no new safety signals have been observed. The company is advancing four phase III key registration clinical trials, among which UC single drugs and combination therapies have been included in the national breakthrough therapy list.